Is Amgen worth $61B to Pfizer?

Yesterday, Deutsche Bank analyst Barbara Ryan proposed a Pfizer-Amgen combo, becoming the third industry watcher to float that particular trial balloon. Today, BNet's Jim Edwards asks, "why not?" If

Sweden to probe AZ's Nobel ties

A Swedish anti-corruption prosecutor says he's launched a criminal probe of this year's Nobel Prize in medicine. Sparked by allegations that AstraZeneca influenced the choice of Harald zur

Health groups try to steer FDA choice

We already know about the heated speculation on the identity of the next FDA commissioner. Now let's talk about the behind-the-scenes lobbying. As the Wall Street Journal reports this morning, health

EU officials seize 34M counterfeit medicines

EU custom officers seized 34 million counterfeit or illegal medicines in a coordinated operation by all 27 states, officials reported earlier this week. The stepped-up effort, dubbed Medi-Fake, was

Pfizer finds buyer for Cork plant

Portuguese contract manufacturer Hovione has purchased Pfizer's Cork, Ireland facility for an undisclosed sum. Pfizer has been trying to find a buyer for the site--which manufactures intermediates

Colon cancer drug shortage raises concerns

There is not a large enough supply of a major colorectal cancer chemotherapy medication, Forbes reports today. The drug is leucovorin, an injectable generic chemotherapy medication, and the shortage

Texas sues J&J's Janssen Pharma

The state of Texas is suing Johnson & Johnson's Janssen Pharmaceuticals, alleging that the drug company used Texas mental health officials as "pitchmen" and carried out other unseemly tactics to

Jury trial granted to fired Amgen whistleblower

Darrell G. Dotson of Newbury Park will have his day in court and bypass Amgen's arbitration process, ruled Ventura County Superior Court judge, Henry Walsh. Amgen fired the former patent lawyer last

Ovation's drug price hike leads to lawsuit

Ovation Pharmaceuticals may be in hot water. The company, which dedicates itself to drugs for rare medical conditions, purchased the rights to Merck's Indocin in 2005, bought a rival drug in 2006 and

FDA mandates warnings for epilepsy meds

The U.S. Food and Drug Administration (FDA) is requiring warnings on a laundry list of antiepileptic medications that say that use of the drugs increases the risk of suicidal thoughts and behaviors.

Bristol-Myers will lay off yet another 10%

Bristol-Myers Squibb will be handing layoff notices to another 10 percent of its 37,000 remaining workers, likely due to weak pipelines, increasing regulatory burdens, looming generic competition and...

Abbott's TriCor follow-up gets FDA nod

Abbott shoots and it scores--finally. The FDA gave the OK to the company's TriLipix cholesterol drug, a follow-up to the highly successful TriCor, which is facing generic competition. The new med is

Generics makers: Canada's rules too tough

A two-year-old lawsuit that argues against rules governing the entrance of generics into the Canadian marketplace goes to a federal court today, with generics makers arguing for a shorter exclusivity

Amgen asks FDA to narrow Vectibix use

To hear the experts tell it, the future of personalized medicine hangs in the balance today. An FDA advisory panel is set to talk over standards for linking genetic tests with cancer drugs. How

Fourth 2008 PML case linked to Tysabri

Another Tysabri patient has contracted the potentially fatal brain infection PML, the fourth case this year. Biogen Idec and its Tysabri partner, Elan, notified regulators of the new diagnosis

FDA chief to step down as Obama's sworn in

It's official: FDA Commissioner Andrew von Eschenbach will step down on inauguration day. The commish announced his plans to FDA staff yesterday, saying that he expects the agency's senior management

Surprise: Pfizer dividend flat, but Lilly's up

Call it a tale of two dividends. For the first time in 42 years, Pfizer is not hiking its quarterly dividend. Hardly shocking in today's economy and today's pharma industry, especially as the company

Gilead sues Teva over HIV med

Gilead Sciences filed a patent infringement lawsuit against Teva Pharmaceutical Industries over the generic drugmaker's move to make a version of the blockbuster HIV treatment Truvada. Release l

Appeals court backs Plavix patent

You can almost hear the celebrations at Bristol-Myers Squibb and Sanofi-Aventis. The two companies saw a U.S. appeals court put its backing behind patent protection for the companies' blockbuster

AstraZeneca outsources IT to India's Infosys

AstraZeneca has inked a big outsourcing deal with India's Infosys, which will maintain IT systems for manufacturing, supply chain, finance, human resources and more. It's a five-year,